Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies
Open Access
- 21 May 2013
- journal article
- research article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 67 (7), 619-632
- https://doi.org/10.1111/ijcp.12194
Abstract
To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. This prespecified pooled analysis of three randomised, double-blind, placebo-controlled, 12-week studies, evaluated efficacy and safety of once-daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and tolterodine ER 4 mg (safety analysis) for the treatment of symptoms of overactive bladder (OAB). Co-primary efficacy measures were change from baseline to Final Visit in the mean number of incontinence episodes/24 h and mean number of micturitions/24 h. Key secondary efficacy end-points included mean number of urgency episodes/24 h and mean volume voided/micturitions, while other end-points included patient-reported outcomes according to the Treatment Satisfaction-Visual Analogue Scale (TS-VAS) and responder analyses [dry rate (posttreatment), ≥ 50% reduction in incontinence episodes/24 h, ≤ 8 micturitions/24 h (post hoc analysis)]. The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate). Mirabegron (50 and 100 mg once daily) demonstrated statistically significant improvements compared with placebo for the co-primary end-points, key secondary efficacy variables, TS-VAS and responder analyses (all comparisons p < 0.05). Mirabegron is well tolerated and demonstrates a good safety profile. The most common AEs (≥ 3%) included hypertension, nasopharyngitis and urinary tract infection (UTI); the incidence of hypertensive events and UTIs decreased with increasing dose. For mirabegron, the incidence of the bothersome antimuscarinic AE, dry mouth, was at placebo level and of a lesser magnitude than tolterodine. The efficacy and safety of mirabegron are demonstrated in this large pooled clinical trial dataset in patients with OAB.Keywords
This publication has 41 references indexed in Scilit:
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU International, 2012
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Prospective pharmacologic therapies for the overactive bladderTherapeutic Advances in Urology, 2009
- SOLIFENACIN IN THE TREATMENT OF URGENCY AND OTHER SYMPTOMS OF OVERACTIVE BLADDER: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RISING-DOSE TRIALBJU International, 2009
- Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trialBJU International, 2008
- Catecholamines Relax Detrusor through β2-Adrenoceptors in Mouse and β3-Adrenoceptors in ManJournal of Pharmacology and Experimental Therapeutics, 2008
- Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapyInternational Journal of Clinical Practice, 2008
- The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC studyBJU International, 2008
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- Role of β‐adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitroNeurourology and Urodynamics, 2003